

INITED STATES DEPARTMENT OF COMMER (sited States Patent and Trademark, Office daws COMMISSIONER FOR PATENTS FD. 80: 149) Alexandre, Virgen 2233-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/725,327	12/02/2003	Katsura Ito	Q78609	2696
7990 06/08/2004			EXAMINER	
SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC 2100 Pennsylvania Avenue, N.W.			NGUYEN, CAM N	
Washington, DC 20037-3213			ART UNIT	PAPER NUMBER
			1754	

DATE MAILED: 06/08/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/725,327	ITO ET AL
Office Action Summary	Examiner	Art Unit
	Cam N Nguyen	1754
- The MAILING DATE of this comm Period for Reply	unication appears on the cover sheet v	vith the correspondence address -
A SHORTENED STATUTORY PERIOD THE MALLING DATE OF THIS COMML Entertains of time may be evaluated under the profess after SIX (6) MONTHS from the making date for roots of the period for regly specified above, the macernar I if No period for regly is specified above, the macernar Failure to regly within the set or extended period for a formal period of the set of	INICATION.  one of 37 CFR 1.136(e). In no event, however, may a minusecation.  y (30) days, a reply within the statutory minimum of this returning on the stetutory produce of the statutory minimum of the stetutory produce of the statutory	reply be timely filed inty (30) days will be considered timely. NTHS from the making date of this communication.
Status		
1) Responsive to communication(s) 2a) This ection is FINAL. 3) Since this application is in condition closed in accordance with the pra	2b) This action is non-final.	tters, prosecution as to the merits is
Disposition of Claims		
4)⊠ Claim(s) <u>1-19</u> is/are pending in the 4a) Of the above claim(s) is 5)□ Claim(s) is/are allowed. 6)⊠ Claim(s) <u>1-19</u> is/are rejected. 7)□ Claim(s) is/are objected to. 8)□ Claim(s) are subject to rest	/are withdrawn from consideration.	
Application Papers		
	e: a) accepted or b) objected to jection to the drawing(s) be held in abeya ng the correction is required if the drawing	nce. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim a) All b) □ Some * c) □ None of:		§ 119(a)-(d) or (f).
1. Certified copies of the priori		
<ol> <li>Certified copies of the priori</li> </ol>	ly documents have been received in A	application No

3. Copies of the certified copies of the priority documents have been received in this National Stage

application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received

2)	Notice of Draftsperson's Patent Drawing Review (PTO-948)
3)(X)	Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/06) Paper No(s)/Mail Date ユロステ
	Paper No(s) Mail Date 4/27 04
18 Pates	r and Traderma's Office

of References Cited (PTO-892)

#### DETAILED ACTION

# Claim Objections

Claim 16 is objected to because of the following informalities:

In line 2, "particle" should be -particles --.

Appropriate correction is required.

# Double Patenting

- 2. The nonstatutory double patenting rejection is based on a justically created doctrine grounded in public policy a policy reflected in the statute) as as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassement by multiple assignees. See her Goodman. 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1983); In re Longt, 759 F.2d 887, 225 USPQ 24 USPQ 24 USPQ 24 USPQ 24 USPQ 26 USPQ
- A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this apolication. See 37 CFR 1.130(b).
- Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).
- Claims 1-18 are rejected under the judicially created doctrine of obviousnesstype double patenting as being unpatentable over claims 1-7, 10, 12-16, & 18-19 of <u>U.S.</u>
   <u>Patent No. 6.683.023 B2</u> (hereinafter Pat '023). Although the conflicting claims are not identical, they are not patentably distinct from each other because of the following

reasons

The difference between the instant claims and the claims of Pat '023, is that the instant claim 1 recites the additional limitation "and wherein the titanium dioxide fine particles are obtained by a vapor phase reaction of a wet-hydrolyzing". However, It is considered that this additional limitation is a product-by-process limitation, which has no bearing on the patentability of the claimed photocatalytic powder. See In <u>m Thorpe</u>. 227 USPQ 964 (Fed. Cir. 1985); In re Brown, 173 USPQ 688, 688 (CCPA 1977); In re Essaman 180 USPQ 324, 326 (CCPA 1977). See also MPEP 2113. It is inherent that the claimed photocatalytic powder is the same the photocatalytic powder set forth in Pat '023 because the same photocatalytic powder is disclosed in both the instant claims and Pat '023.

With respect to claims 2 & 5, it is inherent that the photocatalytic powder of the Pat '023 would possess the same crystal form as the instantly claimed photocatalytic powder because both the instant claims and Pat '023 disclose the same photocatalytic powder.

## Claim Rejections - 35 USC § 102(e)

 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action.

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patient, published under section 122(b), by another fleet in the fulled States before the invention by the applicant for patient (7) a patient granted on an application for patient by another filed in the United States before the invention by applicant for patient, except that an international application filed in outer the treaty defined in section applicant for patient, except that are thereinted application for extra control and the section of an application filed in the United States only if the international application designated the United States and was published under some Article 2(1) or such treaty in the English tanguage.  Claims 1-18 are rejected under 35 U.S.C. 102(e) as being anticipated by Taoda et al., "hereinafter Taoda", (US Pat. 6,090,736).

The applied reference has a common inventors (Ito and Hagihara) with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not dairned in the reference was derived from the inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

Taoda discloses a photocatalytic powder for environment clarification, comprising finely divided titanium dioxide particles having a coating of porous calcium phosphate formed on at least part of the surface of each finely divided titanium dioxide particle, wherein an anionic surface active agent is present at least one the interface between said coating of porous calcium phosphate and the finely divided titanium dioxide particle (see col. 10, claim 1). The finely divided titanium dioxide particle shave an average primary particle diameter of from about 0.001 µm to about 0.2 µm (see col. 10, claim 2). The finely divided titanium dioxide particles are in the form of a powder comprising primary dispersion particles produced by the gaseous phase reaction starting from a titanium halide (see col. 10, claim 3). The anionic surface active agent is disclosed at col. 4, in 27-41. An aqueous slurry used for dispersing the finely divided titanium dioxide particles therein contains an anionic surface active agent and titanium dioxide particles (see col. 10, claim 6). Taoda further discloses when the finely divided titanium

dioxide particle used supports onto the surface thereof a metal, such as platinum, 
rhodium, ruthenium, palladium, silver, copper, iron or zinc, the catalytic action of the 
metal further enhances the environmental clarification effect, such as decompositionremoval of organic compounds or killing of bacteria or molds (see col. 7, in 10-15). The 
photocatalytic powder can be applied to a polymer shaped article, such as an organic 
fiber or a shaped plastic article, composed of an organic polymer. Sultable organic 
polymers including the claimed polymers (see col. 7, in 16-32). Taoda further discloses 
a polymer composition comprising an organic polymer and about 0.01 to about 80% by 
weight, based on the weight of the polymer composition, of a photocatalytic powder for 
environmental clarification; said photocatalytic powder comprising finely divided titanium 
dioxide particles having a coating of porous calcium phosphate formed on at least part 
of the surface of each finely divided titanium dioxide particle, wherein an anionic surface 
active agent is present at least on the interface between said coating of porous calcium 
phosphate and the finely divided titanium dioxide particle (see col. 11-col. 12, claim 11).

Taoda discloses the claimed subject matter, thus anticipates the claims.

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patient may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of his lief, if he differences between the subject matter sought to be patiented and the prior art are such that the subject matter as a whole would have been obtained at the invention was made to a person having ordinary skill in the art to which said subject matter portains. Patientability shall not be negatived by the manner in which the invention was made.

 Claim 19 is rejected under 35 U.S.C. 103(a) as being unpatentable over Taoda et al., "hereinafter Taoda", (US Pat. 6,090,736), as applied to claims 1-18 above, and further in view of Suzuki et al., "hereinafter Suzuki", (US Pat. 5,965,479).

Taoda discloses a photocatalytic powder as described above, except for the activated carbon and/or zeolite.

However, it would have been prima facile obvious to one of ordinary skill in the art at the time the invention was made to have incorporated such known activated carbon into the organic polymer of Taoda to achieve an improved organic polymer having enhanced in removing efficiency of harmful substances, as evidenced by Suzuki (see Suzuki at col. 1, In 19-24). Specifically, Suzuki fairly discloses an activated carbon consisting essentially of activated carbon particle and titanium dioxide fine particles having an average particle size of not more than 10 µm, and containing a suitable binder, including thermosetting resins and the like (see Suzuki at col. 12, claim 1 & col. 8, In 18-34).

#### Citations

 The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Ogawa et al. (US Pat. 6,123,927), Hagihara et al. (US Pat. 6,383,980 B1), Maeda et al. (US Pat. 6,017,993), Hagihara et al. (US Pat. 6,407,156 B1), Taoda et al. (US Pat. 6,291,067 B1), Maeda et al. (US Pat. 6,107,390), Moden et al. (US Pat. 6,241,067), Deller 6,245,140 B1), Lawhome (US Pat. 4,944,936), Deller et al. (US Pat. 5,231,067), Deller Application/Control Number: 10/725,327 Page 7

Art Unit: 1754

et al. (US Pat. 5,366,938), Yao et al. (US Pat. 6,066,359), Komatsu et al. (US Pat. 6,265,341 B1) are cited for related art.

### Conclusion

 Claims 1-19 are originally pending. Claims 1-19 are rejected. No claims are allowed.

 Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Cam Nguyen, whose telephone number is (571) 272-1357. The examiner can normally be reached on M-F from 9:30 am. to 6:00 pm.

The appropriate fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to telephone number (571) 272-1700.

Can Naugen

Nguyen/cnn (An) Primary Examiner

June 04, 2004 Art Unit: 1754